| Name | Title | Contact Details |
|---|---|---|
Kamran Hosseini |
Chief Executive Officer and Co Founder | Profile |
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx`s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.
Caron Products is a provider of incubators & chambers for cell growth and product environmental testing in biological research, scale-up culture, and drug and biological QA/QC testing. Caron`s products are integral to workflows ranging from cell & gene therapy to medical device manufacturing. Caron`s expanding resources, with manufacturing facilities in both the USA and Europe, and a worldwide network of sales and service personnel aligns with the needs of the global biomedical industry.
Glenmark Generics Limited is a Mahwah, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sano Informed Prescribing, Inc. is creating game-changing personal and population health management capabilities, previously unattainable in the healthcare market, by revolutionizing medication therapy through the fast, clinically precise detection of medications in patients. The vision of Sano Informed Prescribing is to improve individual and population health; enable healthcare professionals to evaluate, adjust and implement best possible medication therapy programs; and reduce the costs associated with quality healthcare. Sano Informed Prescribing’s mission is to ensure that every patient receives the most effective drug therapy possible. We will do this by providing precise, patient-specific medication analyses that empower healthcare professionals to tailor care; achieve optimal patient health outcomes and satisfaction; and impact overall healthcare costs.
Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. At Olema we leverage the exquisite knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development.